{"id":"NCT02528214","sponsor":"Sanofi","briefTitle":"Evaluation of Dupilumab in Patients With Severe Steroid Dependent Asthma","officialTitle":"A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Severe Steroid Dependent Asthma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-10-15","primaryCompletion":"2017-09-20","completion":"2017-11-13","firstPosted":"2015-08-19","resultsPosted":"2018-10-23","lastUpdate":"2019-10-01"},"enrollment":210,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"DRUG","name":"Dupilumab","otherNames":["REGN668","SAR231893"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Oral corticosteroid therapy (prednisone/prednisolone)","otherNames":[]},{"type":"DRUG","name":"Inhaled corticosteroid (ICS) therapy","otherNames":[]},{"type":"DRUG","name":"Albuterol/Salbutamol","otherNames":[]},{"type":"DRUG","name":"Levalbuterol/Levosalbutamol","otherNames":[]}],"arms":[{"label":"Placebo q2w","type":"PLACEBO_COMPARATOR"},{"label":"Dupilumab 300 mg q2w","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo evaluate the efficacy of dupilumab, compared with placebo, for reducing the use of maintenance oral corticosteroids (OCS) in participants with severe steroid-dependent asthma.\n\nSecondary Objectives:\n\n* To evaluate the safety and tolerability of dupilumab.\n* To evaluate the effect of dupilumab in improving participants-reported outcomes.\n* To evaluate dupilumab systemic exposure and the incidence of treatment-emergent antidrug antibodies.","primaryOutcome":{"measure":"Percentage Reduction From Baseline in Oral Corticosteroids (OCS) Dose at Week 24 While Maintaining Asthma Control","timeFrame":"Baseline, Week 24","effectByArm":[{"arm":"Placebo q2w","deltaMin":41.85,"sd":4.57},{"arm":"Dupilumab 300 mg q2w","deltaMin":70.09,"sd":4.9}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":10},"locations":{"siteCount":80,"countries":["United States","Argentina","Belgium","Brazil","Canada","Chile","Colombia","Hungary","Israel","Italy","Mexico","Netherlands","Poland","Romania","Russia","Spain","Ukraine"]},"refs":{"pmids":["29782224","36509407","36356712","35809937","35636689","35398549","35217003","34752208"],"seeAlso":["https://www.ncbi.nlm.nih.gov/pubmed/?term=29782224&report=abstract"]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":107},"commonTop":["Viral upper respiratory tract infection","Bronchitis","Sinusitis","Influenza","Eosinophil count increased"]}}